06:12 , Aug 10, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience reverse merging

Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in an all-stock deal. The resulting company will focus on developing Millendo's pipeline for orphan indications. New Enterprise Associates, Frazier...
18:42 , Dec 22, 2017 |  BC Week In Review  |  Company News

Millendo to acquire Alize, gains Prader-Willi candidate

Millendo Therapeutics Inc. (Ann Arbor, Mich.) acquired Alizé Pharma S.A.S. (Lyon, France), an Alizé Pharma (Lyon, France) company, in a stock deal. Financial terms were not disclosed. The former Alizé Pharma S.A.S. facilities will maintain its...
15:01 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

FDA approves Aeterna's Macrilen

FDA approved a resubmitted NDA for Macrilen macimorelin acetate (Macrimorelin-GHST, AEZS-130) from Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) for use in diagnosing adult growth hormone deficiency (AGHD). Aeterna plans to launch the oral ghrelin-mimetic growth hormone...
20:17 , Dec 21, 2017 |  BC Extra  |  Company News

Aeterna jumps on Macrilen approval

Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) shares climbed Thursday after FDA approved a resubmitted NDA for Macrilen macimorelin acetate for use in diagnosing adult growth hormone deficiency (AGHD). Aeterna added C$0.91 (35%) to C$3.48 in Toronto, and...
03:08 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

Ghrelin’s LEAP forward

NGM and MedImmune researchers have discovered a liver peptide, LEAP2, that is a natural antagonist of the metabolic target ghrelin. The peptide could serve as a new handle for either boosting or dampening ghrelin signaling...
04:07 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

EMA reviewing Aeterna Zentaris' Macrilen to evaluate AGHD

EMA accepted for review an MAA from Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) for Macrilen macimorelin acetate (Macrimorelin-GHST, AEZS-130) to evaluate adult growth hormone deficiency (AGHD). A resubmitted NDA for the candidate is under FDA review for...
16:44 , Aug 4, 2017 |  BC Week In Review  |  Clinical News

FDA accepts Aeterna's resubmitted NDA for GHD candidate Macrilen

FDA accepted for review a resubmitted NDA from Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) for Macrilen macimorelin acetate (Macrimorelin-GHST, AEZS-130) to evaluate adult growth hormone deficiency (AGHD). Its PDUFA date is Dec. 30. FDA issued a complete...
19:26 , Jul 31, 2017 |  BC Innovations  |  Distillery Techniques

Imaging

TECHNOLOGY: PET A ghrelin-based PET imaging agent could help diagnose GHSR-expressing ovarian, prostate, testicular and other cancers. Chemical synthesis and in vitro testing of ghrelin analogs in competitive binding assays identified an eight amino acid ghrelin...
20:01 , May 26, 2017 |  BioCentury  |  Emerging Company Profile

Bypassing biopsies

Nanostics Inc. is analyzing biomarkers on tumor-derived vesicles in blood to increase the accuracy of routine prostate cancer screening, and provide a readout of a tumor's aggressiveness. When used with routine PSA screening, the company’s...
19:39 , May 26, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends against Helsinn's Adlumiz

EMA’s CHMP recommended against approval of an MAA from Helsinn Healthcare S.A. (Lugano, Switzerland) for Adlumiz anamorelin (ONO-7643) to treat anorexia, cachexia or unintended weight loss in non-small cell lung cancer (NSCLC) patients. CHMP said their...